Growth factors versus dose reduction for pegylated interferon alfa-2b and ribavirin associated neutropenia and anemia in HIV/HCV co-infected patients

被引：0
|
作者：
Kadam, Jaydeep S.
Jones, Kristina
Peterson, Ray
Dove, Loren
Pearce, Daniel
Hassanein, Tarek
Doonquah, Leeleka
Glesby, Marshal
Heller, Larry
Aboulafia, David
Rodriguez, Jorge
Bonilla, Hector
Galpin, Jeff
Aberg, Judy
Johnston, Barbara
Liu, Ray
Jacobson, Ira M.
Talal, Andrew H.
机构：
来源：
GASTROENTEROLOGY | 2006年 / 130卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A838 / A839
页数：2
相关论文
共 50 条
  • [1] A preliminary study of growth factom versus dose reduction for Peg interferon alfa-2b and ribavirin associated neutropenia and anemia in HIV/HCV co-infected patients
    Golia, P
    Talal, AH
    Jacobson, IM
    Flynn, S
    Golia, P
    GASTROENTEROLOGY, 2003, 124 (04) : A766 - A766
  • [2] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
    Laguno, M
    Murillas, J
    Blanco, JL
    Martínez, E
    Miquel, R
    Sánchez-Tapias, JM
    Bargallo, X
    García-Criado, A
    de Lazzari, E
    Larrousse, M
    León, A
    Loncá, M
    Milinkovic, A
    Gatell, JM
    Mallolas, J
    AIDS, 2004, 18 (13) : F27 - F36
  • [3] Pegylated interferon alfa-2b and ribavirin in HIV/HCV-coinfected patients.
    Myers, RP
    Benhamou, Y
    Bochet, M
    Mehri, D
    Di Martino, V
    Valantin, MA
    Katlama, C
    Bricaire, F
    Poynard, T
    HEPATOLOGY, 2002, 36 (04) : 575A - 575A
  • [4] Pegylated interferon alfa-2b (PEG-IFN) plus ribavirin versus PEG-IFN for treatment of HIV/HCV co-infected patients (pts): An open, multicenter, randomized trial
    Cargnel, A
    Casella, A
    Angeli, E
    Gubertini, G
    Orlando, G
    Duca, P
    GASTROENTEROLOGY, 2002, 122 (04) : A630 - A630
  • [5] The Association of Cytopenias (Anemia, Neutropenia, Lymphopenia, and Thrombocytopenia) with Virologic Response in HIV/HCV Co-infected Patients Treated with Pegylated Interferon Alfa-2a (Peg-IFN2a) and Ribavirin (RBV)
    Slim, Jihad
    Mildvan, Donna
    Han, Jian
    Korner, Eli
    HEPATOLOGY, 2012, 56 : 1011A - 1011A
  • [6] Peginterferon alfa-2b and ribavirin in HIV-HCV co-infected patients: efficacy and safety in routine clinical practice
    Castelo Corral, Laura
    Lopez Calvo, Soledad
    Castro Iglesias, Angeles
    Vazquez Rodriguez, Pilar
    Bello Rodriguez, Laura
    Pedreira Andrade, Jose Domingo
    GALICIA CLINICA, 2010, 71 (04): : 161 - 168
  • [7] Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV
    Dieterich, DT
    Purow, JM
    Rajapaksa, R
    SEMINARS IN LIVER DISEASE, 1999, 19 : 87 - 94
  • [8] IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin
    Osinusi, Anu
    Chary, Aarthi
    Winters, Mark A.
    Naggie, Susanna
    Masur, Henry
    Polis, Michael A.
    Kottilil, Shyam
    Holodniy, Mark
    JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (10) : 1522 - 1527
  • [9] Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial
    Carrat, F
    Bani-Sadr, F
    Pol, S
    Rosenthal, E
    Lunel-Fabiani, F
    Benzekri, A
    Morand, P
    Goujard, C
    Pialoux, G
    Piroth, L
    Salmon-Céron, D
    Degott, C
    Cacoub, P
    Perronne, C
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23): : 2839 - 2848
  • [10] SHORT DURATION THERAPY OF PEGYLATED INTERFERON ALFA-2B PLUS RIBAVIRIN FOR HCV GENOTYPE 2 PATIENTS
    Katano, Yoshiaki
    Ishigami, Mosatashi
    Nakano, Isao
    Hayashi, Kazuhiko
    Honda, Takashi
    Goto, Hidemi
    HEPATOLOGY, 2008, 48 (04) : 1146A - 1147A
12345